Featured Posts

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

Read more: https://www.eurekalert.org/pub_releases/2017-12/sc-idn120717.php

Posts Are Coming Soon
Stay tuned...
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square

524 Bayfield Street North
P.O. Box 20005
Barrie, ON L4M 5E9
Canada

info@opacc.org

1-888-290-5496

  • Wix Facebook page
  • Wix Twitter page
  • Instagram Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon